Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site

被引:67
作者
Herrera, C
Spenlehauer, C
Fung, MS
Burton, DR
Beddows, S
Moore, JP
机构
[1] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA
[2] Tanox Inc, Houston, TX USA
[3] Scripps Res Inst, Dept Immunol, La Jolla, CA USA
[4] Scripps Res Inst, Dept Mol Biol, La Jolla, CA USA
关键词
D O I
10.1128/JVI.77.2.1084-1091.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We have investigated whether nonneutralizing monoclonal antibodies (MAbs) to the gp120 subunit of the envelope glycoprotein (Env) complex of human immunodeficiency virus type 1 (HIV-1) can interfere with HIV-1 neutralization by another anti-gp120 MAb. We used neutralizing (b12) and nonneutralizing (205-42-15, 204-43-1, 205-46-9) MAbs to the epitope cluster overlapping the CD4-binding site (CD4BS) on gp120. All the MAbs, neutralizing or otherwise, cross-competed for binding to monomeric gp120, indicating the close topological proximity of their epitopes. However, the nonneutralizing CD4BS MAbs did not interfere with the neutralization activity of MAb b12. In contrast, in a binding assay using oligomeric Env expressed on the surface of Env-transfected cells, the nonneutralizing MAbs did partially compete with b12 for Env binding. The surface of Env-transfected cells contains two categories of binding site for CD4BS MAbs. One type of site is recognized by both b12 and nonneutralizing CD4BS MAbs; the other is recognized by only b12. Binding assays for Env-gp120 interactions based on the use of monomeric gp120 or Env-transfected cells do not predict the outcome of HIV-1 neutralization assays, and they should therefore be used only with caution when gauging the properties of anti-Env MAbs.
引用
收藏
页码:1084 / 1091
页数:8
相关论文
共 74 条
  • [1] Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
    Baba, TW
    Liska, V
    Hofmann-Lehmann, R
    Vlasak, J
    Xu, WD
    Ayehunie, S
    Cavacini, LA
    Posner, MR
    Katinger, H
    Stiegler, G
    Bernacky, BJ
    Rizvi, TA
    Schmidt, R
    Hill, LR
    Keeling, ME
    Lu, YC
    Wright, JE
    Chou, TC
    Ruprecht, RM
    [J]. NATURE MEDICINE, 2000, 6 (02) : 200 - 206
  • [2] SERUM NEUTRALIZATION OF FELINE IMMUNODEFICIENCY VIRUS IS MARKEDLY DEPENDENT ON PASSAGE HISTORY OF THE VIRUS AND HOST SYSTEM
    BALDINOTTI, F
    MATTEUCCI, D
    MAZZETTI, P
    GIANNELLI, C
    BANDECCHI, P
    TOZZINI, F
    BENDINELLI, M
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (07) : 4572 - 4579
  • [3] Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course
    Beaumont, T
    van Nuenen, A
    Broersen, S
    Blattner, WA
    Lukashov, VV
    Schuitemaker, H
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (05) : 2246 - 2252
  • [4] Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
    Belshe, RB
    Gorse, GJ
    Mulligan, MJ
    Evans, TG
    Keefer, MC
    Excler, JL
    Duliege, AM
    Tartaglia, J
    Cox, WI
    McNamara, J
    Hwang, KL
    Bradney, A
    Montefiori, D
    Weinhold, KJ
    [J]. AIDS, 1998, 12 (18) : 2407 - 2415
  • [5] During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein
    Bendinelli, M
    Pistello, M
    del Mauro, D
    Cammarota, G
    Maggi, F
    Leonildi, A
    Giannecchini, S
    Bergamini, C
    Matteucci, D
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (10) : 4584 - 4593
  • [6] Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins
    Binley, JM
    Sanders, RW
    Master, A
    Cayanan, CS
    Wiley, CL
    Schiffner, L
    Travis, B
    Kuhmann, S
    Burton, DR
    Hu, SL
    Olson, WC
    Moore, JP
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (06) : 2606 - 2616
  • [7] A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
    Binley, JM
    Sanders, RW
    Clas, B
    Schuelke, N
    Master, A
    Guo, Y
    Kajumo, F
    Anselma, DJ
    Maddon, PJ
    Olson, WC
    Moore, JP
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (02) : 627 - 643
  • [8] EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY
    BURTON, DR
    PYATI, J
    KODURI, R
    SHARP, SJ
    THORNTON, GB
    PARREN, PWHI
    SAWYER, LSW
    HENDRY, RM
    DUNLOP, N
    NARA, PL
    LAMACCHIA, M
    GARRATTY, E
    STIEHM, ER
    BRYSON, YJ
    CAO, YZ
    MOORE, JP
    HO, DD
    BARBAS, CF
    [J]. SCIENCE, 1994, 266 (5187) : 1024 - 1027
  • [9] Why do we not have an HIV vaccine and how can we make one?
    Burton, DR
    Moore, JP
    [J]. NATURE MEDICINE, 1998, 4 (05) : 495 - 498
  • [10] Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
    Connor, RI
    Korber, BTM
    Graham, BS
    Hahn, BH
    Ho, DD
    Walker, BD
    Neumann, AU
    Vermund, SH
    Mestecky, J
    Jackson, S
    Fenamore, E
    Cao, Y
    Gao, F
    Kalams, S
    Kunstman, KJ
    McDonald, D
    McWilliams, N
    Trkola, A
    Moore, JP
    Wolinsky, SM
    [J]. JOURNAL OF VIROLOGY, 1998, 72 (02) : 1552 - 1576